Skip to main content

Ranbaxy Laboratories inches ahead

Ranbaxy Laboratories rose 0.15% to Rs 446 at 11:58 IST on BSE after the company said in collaboration with Virchow Biotech, Hyderabad, India it had launched BONISTA- Teriparatide injection for the treatment of Osteoporosis.

The company made this announcement during trading hours today, 3 April 2008.

On BSE, 15,152 shares were traded in the counter. The scrip had an average daily volume of 4.02 lakh shares in the past one quarter.

The stock hit a high of Rs 451.95 and a low of Rs 442.75 so far during the day. The stock had a 52-week high of Rs 490 on 21 November 2007 and a 52-week low of Rs 299.90 on 22 January 2008.

The company's current equity is Rs 186.58 crore. Face value per share is Rs 5.

The current price of Rs 446 discounts its Q4 December 2007 annualized EPS of Rs 5.19, by a PE multiple of 85.93.

Ranbaxy is the first company to launch this bio generic product in the world. The Osteoporosis segment in India has a market size of around Rs 219 crore.

Virchow Biotech is engaged in research, development, manufacture and marketing of a wide range of unique classical biologicals and high value recombinant bio-generic products for serious life-threatening diseases at affordable prices.

On 18 March 2008, Ranbaxy Laboratories (RLL) entered into an exclusive marketing agreement for India and Nepal with CD Pharma for Inersan, a patented probiotic preparation.

In February 2008, RLL received approval from the US Food and Drug Administration to manufacture and market cefuroxime axetil for oral suspension in United States.

RLL's net profit declined 65.2% to Rs 48.40 crore on 1.2% fall in net sales to Rs 993.32 crore in Q4 December 2007 over Q4 December 2006.

Ranbaxy Laboratories is India's largest drug maker

Popular posts from this blog

Bio-fuel has top investors powered up

23RD ,JUNE India's fortune-hunters believe their new-found love for biofuel will pay off. India's well-known investors who are known for their Midas touch have spotted an opportunity in bio-fuel, betting big on ethanol, bio-mass and even bio-fuel equipment makers in India and other parts of the globe. Billionaires Rakesh Jhunjhunwala, C Sivasankaran, Vinod Khosla, founder of Sun Microsystems, and Nemish Shah, the media-shy joint partner of Enam Financial Services, are investing in bio-fuel makers quietly, expecting that bio-fuel will have a big play in the coming years as the world looks for a viable alternative to the fast depleting oil reserves. Jhunjhunwala, who is known for his ability to spot a multi-bagger at a very early stage, recently invested in Hyderabad-based bio-fuel firm Nandan Biometrics.He is also a 10 per cent stakeholder in Praj Industries, which is a bio-fuel technology provider…

up to 8,500% return in 5 years! Investors made a killing in these 30 smallcap stocks

U By Rahul Oberoi, ETMarkets.com | Updated: Dec 01, 2017, 04.06 PM IST Post a Comment
Efficiency pays in the long run. Among the top smallcap plays on Dalal Street, 30 companies with stable return on equity (RoE) and return on capital employed (RoCE) have surged up to 8,500 per cent over the past five years.

All these companies had a debt-to-equity ratio of less than 1 and have been maintaining RoE and RoCE of over 20 per cent since 2012-13.

Avanti Feeds emerged the chart topper, with an 8,527 per cent gain to Rs 2,596.60 as of November 28 from Rs 30.10 ..


ovember 28 from Rs 30.10 on November 27, 2012. The company’s return on equity for FY17, FY16, FY15, FY14 and FY13 stood at 42.65 per cent, 46.21 per cent, 52.41 per cent, 45.79 per cent and 27.60 per cent, respectively. Avanti also managed to achieve a return on capital employed of over 50 per cent in last four years. Its RoCE stood at 28.59 per cent inRoE measures net income earned for every rupee of shareholder funds, while…

5 dark-horse picks

Kwadrat/shutterstock.com Kwadrat/shutterstock.com
If you are a conservative investor, using the mutual fund route is the best way to invest in stocks. But if you are game for some excitement, you might want to dabble directly in stocks, especially small-cap stocks. Stocks that are smaller in size, in terms of market capitalisation, carry higher risk. The reasons are — one, lower traded volume increases price volatility, two, information is usually scarce on these companies, three, business risk is higher since many of these companies are dependent on a single product and four, governance risk is also higher in these stocks. That said, small-cap stocks have the capacity to deliver far greater returns when compared to large-cap stocks. Sample this: there were 16 stocks with market cap more than ₹50,000 crore in January 2009. These stocks delivered an average return of 138 per cent in the last eight years but 4 out of every 10 stocks in this group delivered negative returns. On the ot…